The Italian Covid-eVax vaccine, from Takis and Rottapharm Biotech companies, protects against infection by the SarsCoV2 virus and works against variants: this is indicated by the data obtained in preclinical models, i.e. on mice modified to have the same human Ace receptor used by the virus to invade the cells, and on the basis of which the ongoing Phase 1 and 2 clinical trial was initiated.
The data, presented to an important international journal, are online on the BioRxiv website, which includes works not yet subjected to scrutiny by the scientific community. The vaccine is different from those approved so far in Europe and the United States because it uses DNA technology combined with the electroporation technique, which allows the passage of DNA into cells using short electrical stimuli, developed thanks to the collaboration with another Italian company. , the Igea of Carpi (Modena).
